GlassScriptPhysician profile
Bryan R Hay
NPI 1962778167
$126,335.11
in general payments reported to CMS, 2019-2025
42 companies · $4,355 in 2025
The $4,355 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,167 · 2020: $1,429 · 2021: $5,958 · 2022: $2,672 · 2023: $19K · 2024: $91K · 2025: $4,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $84K · Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Travel and Lodging: $7,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $84,424.57 |
| Food and Beverage | $11,850.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,000.00 |
| Travel and Lodging | $7,834.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $112,012.07 | 2021-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Astrazeneca Pharmaceuticals LP | $2,197.25 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,943.69 | 2019-2025 | Ofev, Spiriva Respimat, Jascayd |
| Glaxosmithkline, LLC. | $1,919.16 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Insmed, INC. | $997.20 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $883.54 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $794.75 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $774.97 | 2019-2025 | Dupixent |
| United Therapeutics Corporation | $569.13 | 2019-2025 | Tyvaso, Tyvaso |
| Inari Medical, INC. | $455.17 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Mylan Specialty L.P. | $454.35 | 2019-2024 | Yupelri |
| Electromed, INC. | $400.10 | 2021-2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $397.71 | 2019-2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $249.84 | 2019-2025 | Zerbaxa, Recarbrio, Winrevair |
| Pfizer INC. | $246.72 | 2019-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $240.00 | 2022 | |
| Amgen INC. | $228.42 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $173.38 | 2022-2024 | Hyqvia, Glassia |
| Penumbra, INC. | $142.22 | 2024 | Indigo System |
| Genentech USA, INC. | $132.04 | 2019-2023 | Xolair |
| Verona Pharma, INC. | $116.31 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $114.29 | 2021-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Viatris Specialty LLC | $99.55 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $85.19 | 2019-2021 | |
| Inspire Medical Systems, INC. | $83.94 | 2023-2025 | Inspire |
| Mallinckrodt Enterprises LLC | $76.37 | 2019 | |
| Novartis Pharmaceuticals Corporation | $60.74 | 2019-2025 | |
| Axsome Therapeutics, INC. | $53.23 | 2023-2024 | Sunosi |
| Baxter Healthcare | $46.08 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Bayer Healthcare Pharmaceuticals INC. | $42.56 | 2019 | |
| Jazz Pharmaceuticals INC. | $41.54 | 2021 | |
| Csl Behring | $24.79 | 2019 | |
| Harmony Biosciences LLC | $23.60 | 2025 | |
| Pulmonx Corporation | $23.58 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| E.R. Squibb & Sons, L.L.C. | $22.25 | 2022 | |
| Lilly USA, LLC | $21.77 | 2025 | Zepbound |
| 3b Medical, INC. | $21.34 | 2025 | Luna |
| Ani Pharmaceuticals, INC. | $19.78 | 2025 | Purified Cortrophin Gel |
| Azurity Pharmaceuticals, INC. | $19.38 | 2025 | Alvesco |
| Circassia INC. | $16.05 | 2019 | |
| Gilead Sciences, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Hay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.